Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Blood and lymph test 1 > Mata > Flashcards

Mata Flashcards

1
Q

Erythocyte factors

A

Iron
Vitamins B12 and folate
EPO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Granulocyte factors

A

Filgastim (g-CSF)

Sargramastim (GM-CSF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Platelet factors

A

Oprelvekin (IL11)
Romiplostim
Eltrombopag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Most common causes of iron and vitamin diff.

A
  • menstruation in females
  • drug treatment w/ NSAIDS (blood loss)
  • pathological conditions
  • parasitic infestation.
  • Pregnancy and child bearing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Iron uptake

A

Abs in duodenum/proximal jejunum
Give at 2 hrs before or 4 hours after food
Do not give with phosphates/phyates/tannates
Abs. better with Acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  1. Iron dextran– Low (InFeD®) and high (DexFerrum®) MW
A

IV/IM bolus or IV infusion (for large doses)

Because of allergic reactions a test dose infusion can be performed when giving this agent for the first time.

Indications
	Excessive continuing blood loss
	Inflammatory bowel disease
	Chronic kidney disease
	Use in cancer patients
	Use in heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. Ferric Gluconate Complex (Ferrlecit®)
A

Commonly used with EPO
1 hr IV infusion, lower incidence of hypersensitivity reactions than HMW dextran
The potential exists for fatal hypersensitivity reactions and test doses are recommended in patients with drug allergies including iron dextran.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. Iron Sucrose (Venofer®)
A

 safe and effective for many conditions that require parental iron supplementation
 rountinely used in combination with erythropoietin during hemodialysis to prevent Fe deficiency anemia from loss of RBC during dialysis +  RBC production.
 Unlike other parental formulations iron sucrose is not used for total dose infusions and is limited to 300 mg every 2-3 weeks.
 total dose infusions – repeleting iron stores with a single treatment episode

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Ferumoxytol (Feraheme®)

A

composed of superparamagnetic iron oxide nanoparticles coated with a low molecular weight semisynthetic carbohydrate.
It has been deemed safe and effective when given as a rapid intravenous infusion (> 1 min) in patients with chronic kidney disease (CKD) and those on dialysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

. Ferric carboxymaltose (Ferinject®)

A

is a novel stable iron complex for intravenous use that can be given at single doses of up to 1000 mg of elemental iron per week over a recommended infusion time of 15 minutes.
Approved in July 2013 up to 1500 mg of iron can be administered over the course of two treatment sessions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Side effects of IV iron

A

 Self-limiting fever, arthralgias, and myalgias, usually within 24 hours of infusions. These resolve without therapy but a small clinical benefit is obtained from the use of nonsteroidal anti-inflammatory agents.
 A flare of arthritis in patients with inflammatory arthritis, such as rheumatoid arthritis, commonly occurs. (steroids?)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Chelation therapy for iron toxicity

A

Treatment for acute toxicity: deferoxamine

Treatment of chronic toxicity: deferoxamine or deferasirox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Vitamin B12= Cyanocobalamin

A
  • B12 is complexed w/ intrinsic factor and absorbed via a highly selective receptor-mediated transport system.
  • Transcobalamin II – systemic transport
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

B12 is maintained as two important active coenzymes

A

a) Methylcobalamin: utilized for synthesis of methionine from homocysteine
b) Deoxyadenosylcobalamin: responsible for carbohydrate and lipid metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

B12 vs intrinsic factor anemias

A

B12- Megaloblastic (RBC first) and can have irrreversible neuro damage characterized by swelling of myelinated neurons, demyelination and cell death in spinal chord & cortex

Intrinsic- Pernicious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

B12 drugs

A

Hydroxocobalamin (Generic) – IM Only
Cyanocobalamin (Generic) – IM /Deep SQ
Intranasal Gel (Nascobal)

Can also supplement folate to correct B12 problem but not resolve myelination problem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Folic acid

A

Used in myelination and in DNA synthesis
• DEFICIENCY  Megaloblastic Anemia indistinguishable from that caused by B12 deficiency.
• ANEMIA will appear more rapidly with folate deficiency than with B12 deficiency because there is a limited storage pool.
• Folic acid DOES NOT lead to neurological abnormalities
• Higher strengths + injectable require prescription

18
Q

Erythropoietin - a.k.a. Epoetin Alfa or EPO (Epogen

A

 Erythropoietin binds to the erythropoietin receptor (EpoR) on red cell progenitors and precursors and promotes survival and proliferation.
 Titrate dose to prevent too rapid ↑ in Hct .
 Patients must have adequate Fe in circulation before therapy initiated
 Rapid expansion of red cell mass can ↑ blood volume & viscosity leading to↑ vascular resistance.
 Erythropoietins increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence
Made in kidney

19
Q

Three formulations all given by injection IV or SC

A
  1. Erythropoietin - a.k.a. Epoetin Alfa or EPO (Epogen®) Recombinant form of erythopoietin 3x / week
  2. Darbepoetin alfa - (Aranesp®) 1x/week
  3. Methoxy polyethylene glycol-epoetin - (Mircera®) 1-2X/month
    Uses:
     Anemias, particularly those associated with chronic renal failure (CRF).
     Adjunct to drugs therapies that cause bone marrow suppression & anemias.
    (e.g. zidovudine to AIDS patients, granulocytopenia and anemia, cancer chemotherapy related bone marrow supression and anemias.
     During elective non-cardiac/non-vascular surgery to ↓ need for transfusions
20
Q

Filgrastim

Two preparations: natural and PEG compound

A

granulocyte colony stimulating factor, G-CSF
 Stimulates proliferation of progenitor cells committed to the neutrophil lineage
 Activates neutrophil phagocytic activity
 Prolongs their lifetime
 Mobilize hematopoietic stem cells
Longer duration, injected once every few weeks
Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. It controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time.
Pegylation reduces clearance via glomerular filtration, cleared via NEUTROPHILS ONLY

21
Q

Granulocyte Colony-stimulating Factor (G-CSF)

A

USES: To Treat severe neutropenia following:
1. Autologous marrow transplants  ↓ morbidity due to bacterial/fungal infections
2. Cancer chemotherapy.  ↓ hospitalization for febrile neutropenia.
3. Severe congenital neutropenia.
4. Neutropenia in AIDS patients on zidovudine
SIDE EFFECTS:
• Bone pain (mild-moderate)
• Local skin reactions if given S.C.
• Prolonged treatment can  marked GRANULOCYTOSIS that resolves with cessation of treatment.

22
Q

Myeloid Growth Factors

A

Sargramostim - granulocyte-macrophage colony stimulating factor, GM-CSF
 Broader stimulatory activity
 Similar Neutrophil stimulatory activity

Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils.

Pegylation reduces clearance via glomerular filtration, cleared via NEUTROPHILS ONLY

23
Q

SARGRAMOSTIM (Leukine

A

Acts similar to G-CSF but with broader spectrum.
USES:
1. Autologous marrow transplants to shorten duration of neutropenia  ↓ morbidity
2. Shorten neutropenia & ↓ morbidity in chemotherapy & AIDS-related neutropenia.
3. Effective in some patients with aplastic anemia or myelodysplasia.
SIDE EFFECTS
HIGHER DOSES Bone pain / malaise / fever / diarrhea / dyspnea / rash.

1ST Dose Acute Reaction: reaction to first infusion (may include face flushing, trouble breathing, dizziness)

24
Q

Oprelvekin (Neumega®)

A

– recombinant form of endogenous cytokine IL-11.
• MOA: Stimulates the growth of primitive megakaryocytic progenitors, Increases peripheral platelets and neutrophils
• Clinical Use: Thrombocytopenia and reduces the need for platelets.
• Side Effects: fatigue, headache, dizziness, and cardiovascular effects.
• Major Complication – FLUID RETENTION (indicative of peripheral edema or dyspnea on exertion) CAUTION if CHF.

25
Q

ROMIPLOSTIM (Nplate®)

A

new therapeutic class “peptibodies”. Genetically engineered protein in which Fc components of a human antibody are fused to multiple copies of a peptide that stimulates the thromboplastin receptors.

26
Q

ELTROMBOPAG (Promacta

A

Orally active thromboplastin receptor agonist.

• SIDE EFFECT: ability to cause HEPATOTOXICITY and HEMORRHAGES

27
Q

Nucleoside Reverse Transcriptase Inhibitors

A
  1. NRTIs must first undergo intracellular phosphorylation to be active
  2. NRTIs inhibit the viral reverse transcriptase enzyme (Enzyme responsible for transcribing viral RNA into double stranded DNA)
  3. NRTIs mimic other nucleosides and are incorporated into the DNA strand
  4. They prevent the addition of the natural nucleosides into the DNA strand
  5. This halts the production of new virions
28
Q

Some of the more common NRTI’s

A

Zidovudine (AZT)
Tenofovir (already phosphorylated)
Abacavir

Mainly undergo renal excretion EXCEPT
 Zidovudine (AZT) undergoes glucuronidation
 Abacavir (ABC) metabolized by alcohol dehydrogenase
 Do not have P-450 drug interactions

29
Q

Highly active antiretroviral therapy (HAART) toxicity

A

NRTI-related mitochondrial toxicity, which manifests as serious side effects such as hepatic failure with steatosis and lactic acidosis

30
Q

NRTI’s resistance

A

Can descriminate

Can remove

31
Q

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

A

Nevirapine (NVP, Viramune™)
Delavirdine (DLV, Rescriptor™) rarely used
Efavirenz (EFV, Sustiva™) Most potent

Advantage: long half life
Disadvantage: Greater risk of resistance at the time of treatment leading to failure than with PIs
 Potential for cross resistance
 Skin rash
 Transmitted resistance more common than with protease inhibitors.
 Single mutation confers cross resistance to all available NNRTIs
Metabolism
Hepatic metabolism by cytochrome P450s
-no renal dosage adjustments required
Adverse Reaction with NNRTIs:
Efavirenz
 CNS adverse effects, such as abnormal dreams, dizziness, headache, and depression, which usually resolve.

32
Q

Protease Inhibitors

A

End with Navir
Advantages:
 Higher genetic barrier to resistance than NNRTIs and Integrase inhibitor (Raltegravir)
 PI resistance at the time of treatment failure uncommon with RTV-boosted Pis
Disadvantages:
 Metabolic complications such as dyslipidemia, insulin resistance, and hepatotoxicity
 GI adverse effects
 CYP3A4 inhibitors and substrates: potential for drug interactions Adolescents

33
Q

Ritonavir (Norvir™)

A

Ritonavir induces it own metabolism and it is one of the most potent CYP3A4 inhibitors known. “boosting.

This increases AUC, Cmax, Cmin and t1/2, thus the bioavailability of the boosted protease inhibitor is increased and improved penetration into HIV reservoirs may be achieved.

34
Q

Fusion Inhibitors

A

Maraviroc (Selzentry™), Enfuvirtide (Fuzeon™)

35
Q

Enfuvirtide (Fuzeon™)

A

Enfuvirtide (Fuzeon™)
Mechanism of Action
– 36 AA synthetic peptide, SC bid.
 Inhibits entry of HIV into the CD4 cell
 T-20 binds to glycoprotein gp41 (a protein on the viral membrane)
 This binding prevents a change in the shape of the membrane protein and prevents fusion of the virus and the CD4 cell membrane

36
Q

Maraviroc (Selzentry™)

A

Binds CCR5
Adverse effects/precautions:
 Hepatotoxicity may be preceded by a systemic allergic reaction (pruritic rash, eosinophilia)
 Dizziness/postural hypotension
 Increased risk of CV events (MI, ischemic events)

37
Q

Integrase Inhibitor

A

end with gravir
Mechanism of Action
 Integrase Strand Transfer Inhibitor (INSTI)
 Blocks catalytic activity of the HIV – encoded integrase preventing integration of viral DNA into the host chromosome
 Potent activity against HIV-1 and 2
 Active against HIV strains resistant to other antiretroviral agents

38
Q

Integrase Inhibitor drugs

A

Raltegravir (RAL)

Elvitegravir (EVG)

39
Q

Elvitegravir (EVG)

A

is an INSTI available as a fixed-dose combination product with cobicistat (COBI), tenofovir disoproxil fumarate (TDF,) and emtricitabine (FTC) (EVG/COBI/TDF/FTC), and is approved as a single-tablet, once-daily regimen for ART-naive patients.
EVG is metabolized primarily by CYP3A enzymes; as a result, CYP3A inducers or inhibitors may alter EVG concentrations.
COBI is a specific, potent CYP3A inhibitor with no activity against HIV. It acts as a PK enhancer of EVG, which allows for once daily dosing of the combination product

40
Q

Elvitegravir side effects include

A

nausea and diarrhea,
upper respiratory tract infections and broncitis,
back and joint pain and
urinary tract infections
Keep in mind that this drug is only approved to be used with cobicistat a potent p4503A4 inhibitor.

Blood and lymph test 1 (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions